Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets (2016 - 2025)

Historic Assets for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $823.6 million.

  • Corcept Therapeutics' Assets rose 501.75% to $823.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $823.6 million, marking a year-over-year increase of 501.75%. This contributed to the annual value of $840.6 million for FY2024, which is 3524.22% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Assets is $823.6 million, which was up 501.75% from $801.7 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Assets peaked at $846.5 million during Q1 2025, and registered a low of $423.8 million during Q4 2021.
  • Moreover, its 5-year median value for Assets was $594.0 million (2023), whereas its average is $633.5 million.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 2588.19% in 2021, then surged by 3768.06% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Assets (Quarter) stood at $423.8 million in 2021, then soared by 37.68% to $583.4 million in 2022, then increased by 6.53% to $621.5 million in 2023, then skyrocketed by 35.24% to $840.6 million in 2024, then dropped by 2.02% to $823.6 million in 2025.
  • Its Assets stands at $823.6 million for Q3 2025, versus $801.7 million for Q2 2025 and $846.5 million for Q1 2025.